Royalty Pharma Plc Earnings

Royalty Pharma Plc’s revenue jumped 7.71% since last year same period to $578.67Mn in the Q2 2025. On a quarterly growth basis, Royalty Pharma Plc has generated 1.83% jump in its revenue since last 3-months.

Royalty Pharma Plc’s net profit fell -70.42% since last year same period to $30.18Mn in the Q2 2025. On a quarterly growth basis, Royalty Pharma Plc has generated -87.34% fall in its net profits since last 3-months.

Royalty Pharma Plc’s net profit margin fell -72.53% since last year same period to 5.21% in the Q2 2025. On a quarterly growth basis, Royalty Pharma Plc has generated -87.57% fall in its net profit margins since last 3-months.

Royalty Pharma Plc’s price-to-earnings ratio after this Q2 2025 earnings stands at 15.86.

Royalty Pharma Plc’s earning per share (EPS) estimates for the current quarter stand at 1.05 - a 1.94% jump from last quarter’s estimates.

Royalty Pharma Plc’s earning per share (EPS) estimates for the current year stand at 1.05.

Royalty Pharma Plc’s earning per share (EPS) fell -100% since last year same period to 0 in the Q3 2025. This indicates that the Royalty Pharma Plc has generated -100% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Royalty Pharma Plc declared 0.22 dividend per share during the earnings announcement for Q3 2025.